fda-and-biotech News
Pfizer Posts Strong Phase 3 Data for Hemophilia Drug HYMPAVZI
Once-weekly treatment shows a 93% reduction in bleeding rates for patients with inhibitors, positioning Pfizer in a competitive market.
Corbus Pharma Shares Drop After Pricing $75M Offering at 20% Discount
The clinical-stage biotech is capitalizing on a recent stock surge to fund its promising oncology and obesity drug pipeline, despite the dilutive terms for current shareholders.
4DMT Surges on Otsuka Gene Therapy Deal for Asia-Pacific Market
The biotech firm secures an $85 million upfront payment and a strategic partnership to commercialize its key eye disease treatment, 4D-150.
Liminatus Pharma Jumps on $30 Million Investment MOU
Clinical-stage biotech signs non-binding agreement with Capital Trust Group, representing a significant potential cash infusion for its immunotherapy research.
Arcus Executives Divest Stock Following 60% Surge
Chief Operating Officer and Chief Financial Officer sell shares under pre-planned trading schedules as the biotech company's stock nears its 52-week high.
Oculis Shares Rise After $110 Million Capital Raise for Vision Drugs
Oversubscribed financing signals strong investor confidence in the Swiss biotech's pipeline, particularly its novel neuroprotective candidate, privosegtor.
Neumora Backers Hold 20% Stake Ahead of Key Depression Drug Data
Founding investor ARCH Venture Partners reaffirms deep conviction with a 20.6% beneficial ownership stake as the biotech's pivotal Phase 3 trial nears.
Savara Stock Dips After Announcing Public Share Offering
The biotech firm is raising capital to fund its lead lung disease drug following a regulatory setback earlier this year, a move that could dilute existing shareholder value.